Versión de HTML Básico
42
Manuel Lobo González
Células madre en terapia celular cardíaca
have increased arterial vulnerability to metabolic risk factors: the Car-
diovascular Risk in Young Finns Study. Arterioscler Thromb Vasc Biol.
2006;26:1376-82.
4. Haffner SM. Metabolic syndrome, diabetes and coronary heart
disease. Int J Clin Pract Suppl. 2002 Oct;(132):31-7.
5. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP,
et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease
and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk
Reduction for Adult Patients Without Coronary or Other Atherosclero-
tic Vascular Diseases. American Heart Association Science Advisory and
Coordinating Committee.Circulation. 2002 Jul 16;106:388-91.
6. Nissen SE. Who is at risk for atherosclerotic disease? Lessons
from intravascular ultrasound. Am J Med. 2002 Jun 3;112.
7. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown
TM, et al; American Heart Association Statistics Committee and Stroke
Statistics Subcommittee.Heart disease and stroke statistics—2011 upda-
te: a report from the American Heart Association.Circulation. 2011 Feb
1;123:e18-e209
8. Poon E, Kong CW, Li RA.Human pluripotent stem cell-based ap-
proaches for myocardial repair: from the electrophysiological perspective.
Mol Pharm. 2011 3;8:1495-504.
9. Anversa P, Leri A, Rota M, Hosoda T, Bearzi C, Urbanek K, Kaj-
stura J, Bolli R .Concise review: stem cells, myocardial regeneration, and
methodological artifacts.Stem Cells. 2007;25:589-601.
10. Balsam LB, Robbins RC Haematopoietic stem cells and repair of
the ischaemic heart. Clin Sci (Lond) 2005: 109, 483-492.
11. Fukuda K. Progress in myocardial regeneration and cell trans-
plantation. Circ J 2005: 69, 1431-1446.
12. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti
S, et al. Adult cardiac stem cells are multipotent and support myocardial
regeneration. Cell 2003:114, 763-776.
13. Urbanek K, Torella D, Sheikh F, De Angelis A, Nurzynska D, Sil-
vestri F, et al. Myocardial regeneration by activation of multipotent car-
diac stem cells in ischemic heart failure. Proc Natl Acad Sci USA 2005:102,
8692-8697.
14. Torella D, Ellison GM, Nadal-Ginard B, Indolfi C. Cardiac stem
and progenitor cell biology for regenerative medicine. Trends Cardiovasc
Med 2005:15, 229-236.
15. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina
Y, et al. Cardiac progenitor cells from adultmyocardium: homing, diffe-
rentiation, and fusion after infarction.Proc Natl Acad Sci U S A. 2003;100:
12313-8.
16. Urbanek K, Cesselli D, Rota M, Nascimbene A, De Angelis A, Ho-
soda T, et al. Stem cell niches in the adult mouse heart. Proc Natl Acad Sci
USA 2006:103, 9226-9231.
17. Urbanek K, Quaini F, Tasca G, Torella D, Castaldo C, Nadal-Ginard
B, et al. Intense myocyte formation from cardiac stem cells in human car-
diac hypertrophy. Proc Natl Acad Sci USA 2003:100, 10440-10445.
18. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabé-
Heider F, Walsh S, et al. Evidence for cardiomyo-cyte renewal in humans.
Science 2009; 324: 98-102.
19. Doris A. Taylor, Matthew J. Robertson .The basics of cell therapy
to treat cardiovascular disease: One cell does not fit all. Rev Esp Cardiol
2009;62:1032-1044.
20. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Ber-
man D, et al. Intracoronary cardiosphere-derived cells for heart regenera-
tion after myocardial infarction (CADUCEUS): a prospective, randomised
phase 1 trial. Lancet 2012; 10;379(9819):895-904
21. Bolli R. The late phase of preconditioning. Circ Res 2000; 87:972-
983.
22. Zaruba MM, Soonpaa M, Reuter S, Field LJ. Cardiomyogenic po-
tential of C-kit (+)-expressing cells derived from neonatal and adult mouse
hearts. Circulation. 2010 11;121:1992-2000.
23. Fazel S, Cimini M, Chen L, Li S, Angoulvant D, Fedak P, et al.
Cardioprotective c-kit+ cells are from the bone marrow and regulate the
myocardial balance of angiogenic cytokines.J Clin Invest. 2006 ;116:1865-
77.
24. Chugh AR, Beache GM, Loughran JH, Mewton N, Elmore JB, Kaj-
stura J, et al.Administration of cardiac stem cells in patients with ischemic
cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of
myocardial function and viability by magnetic resonance.Circulation. 2012
11;126:S54-64
25. Invernici G, Cristini S, Madeddu P, Brock S, Spillmann F, Bernas-
coni P, et al. Human adult skeletal muscle stem cells differentiate into car-
diomyocyte phenotype in vitro.Exp Cell Res. 2008 15;314:366-76
26. Menasché P, Alfieri O, Janssens S, McKenna W, Reichenspurner
H, Trinquart L, et al. The Myoblast Autologous Grafting in Ischemic Car-
diomyopathy (MAGIC) trial: first randomized placebo-controlled study of
myoblast transplantation. Circulation 2008;117:1189–200.
27. McCue JD, Swingen C, Feldberg T, Caron G, Kolb A, Denucci C, et
al. The real estate of myoblast cardiac transplantation: negative remode-
ling is associated with location. J Heart Lung Transplant. 2008;27:116-23.
28. Veltman CE, Soliman OI, Geleijnse ML, Vletter WB, Smits PC,
ten Cate FJ, et al. Four-year follow-up of treatment with intramyocardial
skeletal myoblasts injection in patients with ischaemic cardiomyopathy.
Eur Heart J. 2008;29:1386-96.
29. Narita T, Shintani Y, Ikebe C, Kaneko M, Harada N, Tshuma N,
et al. The use of cell-sheet technique eliminates arrhythmogenicity of
skeletal myoblast-based therapy to the heart with enhanced therapeutic
effects. Int J Cardiol. 2012 Oct 6 (in press)
30. Povsic TJ, O’Connor CM, Henry T, Taussig A, Kereiakes DJ, For-
tuin FD, et al. A double-blind, randomized, controlled, multicenter study
to assess the safety and cardiovascular effects of skeletal myoblast im-
plantation by catheter delivery in patients with chronic heart failure after
myocardial infarction. Am Heart J. 2011; 162:654-662.
31. Chong JJ, Chandrakanthan V, Xaymardan M, Asli NS, Li J, Ahmed
I, et al. Adult cardiac-resident MSC-like stem cells with a proepicardial ori-
gin. Cell Stem Cell 2011;9:527–40.
32. Tomita S, Li RK, Weisel RD, Mickle DA, Kim EJ, Sakai T, et al. Au-
tologous transplantation of bone marrow cells improves damaged heart
function. Circulation 1999;100 (suppl):II247-II256.
33. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchy- mal
stem cells reside in virtually all post-natal organs and tissues. J Cell Sci
2006;119:2204–13.
34. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, et
al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J
Clin Invest. 1999;103:697-705.
35. Mazhari R, Hare JM. Mechanisms of action of mesenchymal
stem cells in cardiac repair: potential influences on the cardiac stem cell
niche. Nat Clin Pract Cardiovasc 2007;4(suppl 1):S21-S26.
36. Schuleri KH, Amado LC, Boyle AJ, Centola M, Saliaris AP, Gutman
MR, et al. Early improvement in cardiac tissue perfusion due to mesenchy-
mal stem cells.Am J Physiol Heart Circ Physiol. 2008;294:H2002-H2011.
37. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human
mesenchymal stem cells differentiate to a cardiomyocyte phenotype in
the adult murine heart.Circulation 2002;105:93-98.
38. Aggarwal S, Pittenger MF. Human mesenchymal stem cells mo-
dulate allogeneic immune cell responses. Blood 2005: 15;105:1815-1822.
39. Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM,
Deans R, et al. Human mesenchymal stem cells engraft and demonstra-
te site-speci”c differentiation after in utero transplantation in sheep. Nat
Med.2000;6:1282-1286.
40. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic
mediators.J Cell Biochem. 2006 1;98:1076-84.
41. Planat-Bénard V, Menard C, André M, Puceat M, Perez A, Garcia-
Verdugo JM, et al. Spontaneous cardio- myocyte differentiation from adi-
pose tissue stroma cells. Circ Res. 2004; 94:223-229.